In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Finding The Fit For Ophthalmology In The New Pfizer

Executive Summary

The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.


Related Content

M&A Deals Drop In 2015, With IVD-Sector Transactions Still Leading The Pack
Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)
Ophthalmology Surgeons, Companies Finding Solutions In Medtech


Related Companies

Related Deals